Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12931-015-0269-4 http://scihub22266oqcxt.onion/10.1186/s12931-015-0269-4 C4570597!4570597!26369563     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Respir+Res 2015 ; 16 (1): ä Nephropedia Template TP {{tp|p=26369563|t=2015. The Tiotropium Safety and Performance in RespimatŪ (TIOSPIRŪ) Trial: Spirometry Outcomes |pdf=|usr=}}{{26369563}} gab.com Text The Tiotropium Safety and Performance in RespimatŪ (TIOSPIRŪ) Trial: Spirometry Outcomes JO: Respir Res http://www.kidney.de/pget.php?&tw=1&pmid=26369563 #FOAvip Background: Tiotropium Safety and Performance in RespimatŪ (TIOSPIRŪ) compared the safety and efficacy of tiotropium RespimatŪ and tiotropium HandiHalerŪ in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIRŪ was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24 weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium RespimatŪ 5 ?g (n?=?461), 2.5 ?g (n?=?464), or tiotropium HandiHalerŪ 18 ?g (n?=?445). Adjusted mean trough FEV1 (average 24?120 weeks) was 1.285, 1.258, and 1.295 L in the RespimatŪ 5 ?g, 2.5 ?g, and HandiHalerŪ 18 ?g groups (difference versus HandiHalerŪ [95 % CI]: ?10 [?38, 18] mL for RespimatŪ 5 ?g and, ?37 [?65, ?9] mL for RespimatŪ 2.5 ?g); achieving noninferiority to tiotropium HandiHalerŪ 18 ?g for tiotropium RespimatŪ 5 but not for 2.5 ?g (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593 L in the RespimatŪ 5 ?g, 2.5 ?g, and HandiHalerŪ 18 ?g groups. The rates of FEV1 decline over 24 to 120 weeks were similar for the three treatment arms (26, 40, and 34 mL/year for the tiotropium RespimatŪ 5-?g, 2.5-?g, and HandiHalerŪ 18-?g groups). The rate of FEV1 decline in GOLD I?+?II patients was greater than in GOLD III?+?IV patients (46 vs. 23 mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIRŪ spirometry substudy showed that tiotropium RespimatŪ 5 ?g was noninferior to tiotropium HandiHalerŪ 18 ?g for trough FEV1, but RespimatŪ 2.5 ?g was not. Tiotropium RespimatŪ 5 ?g provides similar bronchodilator efficacy to tiotropium HandiHalerŪ 18 ?g with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration: NCT01126437. Electronic supplementary material: The online version of this article (doi:10.1186/s12931-015-0269-4) contains supplementary material, which is available to authorized users. Twit Text FOAVip The Tiotropium Safety and Performance in RespimatŪ (TIOSPIRŪ) Trial: Spirometry Outcomes ????Respir Res http://www.kidney.de/pget.php?&tw=1&pmid=26369563 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26369563 #FOAvip English Wikipedia <ref>{{Cite pmid|26369563}}</ref> The Tiotropium Safety and Performance in RespimatŪ (TIOSPIRŪ) Trial: Spirometry Outcomes #MMPMID26369563 Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R Respir Res 2015[]; 16 (1): ä PMID26369563show ga Background: Tiotropium Safety and Performance in RespimatŪ (TIOSPIRŪ) compared the safety and efficacy of tiotropium RespimatŪ and tiotropium HandiHalerŪ in patients with chronic obstructive pulmonary disease (COPD). A prespecified spirometry substudy compared the lung function efficacy between treatment groups. Methods: TIOSPIRŪ was a large-scale, long-term (2.3-year), event-driven, randomized, double-blind, parallel-group trial of 17,135 patients with COPD. In the spirometry substudy, trough forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were measured at baseline and every 24 weeks for the duration of the trial. Results: The substudy included 1370 patients who received once-daily tiotropium RespimatŪ 5 ?g (n?=?461), 2.5 ?g (n?=?464), or tiotropium HandiHalerŪ 18 ?g (n?=?445). Adjusted mean trough FEV1 (average 24?120 weeks) was 1.285, 1.258, and 1.295 L in the RespimatŪ 5 ?g, 2.5 ?g, and HandiHalerŪ 18 ?g groups (difference versus HandiHalerŪ [95 % CI]: ?10 [?38, 18] mL for RespimatŪ 5 ?g and, ?37 [?65, ?9] mL for RespimatŪ 2.5 ?g); achieving noninferiority to tiotropium HandiHalerŪ 18 ?g for tiotropium RespimatŪ 5 but not for 2.5 ?g (prespecified analysis). Adjusted mean trough FVC was 2.590, 2.544, and 2.593 L in the RespimatŪ 5 ?g, 2.5 ?g, and HandiHalerŪ 18 ?g groups. The rates of FEV1 decline over 24 to 120 weeks were similar for the three treatment arms (26, 40, and 34 mL/year for the tiotropium RespimatŪ 5-?g, 2.5-?g, and HandiHalerŪ 18-?g groups). The rate of FEV1 decline in GOLD I?+?II patients was greater than in GOLD III?+?IV patients (46 vs. 23 mL/year); as well as in current versus ex-smokers, in patients receiving combination therapies at baseline versus not, and in those experiencing an exacerbation during the study versus not. Conclusions: The TIOSPIRŪ spirometry substudy showed that tiotropium RespimatŪ 5 ?g was noninferior to tiotropium HandiHalerŪ 18 ?g for trough FEV1, but RespimatŪ 2.5 ?g was not. Tiotropium RespimatŪ 5 ?g provides similar bronchodilator efficacy to tiotropium HandiHalerŪ 18 ?g with comparable rates of FEV1 decline. The rate of FEV1 decline varied based on disease severity, with a steeper rate of decline observed in patients with moderate airway obstruction. Trial registration: NCT01126437. Electronic supplementary material: The online version of this article (doi:10.1186/s12931-015-0269-4) contains supplementary material, which is available to authorized users. äThe Tiotropium Safety and Performance in RespimatŪ (TIOSPIRŪ) Trial: S(epmc).pdf DeepDyve Pubget Overpricing